Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael A. Kiebish, Poornima Tekumalla, Shobha Ravipaty, Albert Dobi, Shiv Srivastava, Wenfang Wu, Saurabh Patil, Tracey Friss, Allison Klotz, Alagarsamy Srinivasan, Jennifer Cullen, Inger L. Rosner, Amina Ali, Sandra Laszlo, Michele Petrovic, Neil Fleshner, Jeonifer Garren, Greg Miller, Nischal Mahaveer Chand, Leonardo O. Rodrigues, Elder Granger, Mark D. Kellogg, Shen Luan, Eleftherios Diamandis, Viatcheslav R. Akmaev, Rangaprasad Sarangarajan, Chas Bountra, Stephen J. Freedland, David G. McLeod, Niven R. Narain
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Ejemplares similares